TNGX logo

Tango Therapeutics Inc. (TNGX)

$22.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TNGX

Market cap

$3.75B

EPS

-1.37

P/E ratio

--

Price to sales

74.61

Dividend yield

--

Beta

1.258635

Price on TNGX

Previous close

$24.17

Today's open

$24.08

Day's range

$22.05 - $24.32

52 week range

$7.69 - $34.39

Profile about TNGX

CEO

Malte Peters

Employees

137

Headquarters

Boston, MA

Exchange

NASDAQ Global Market

Shares outstanding

169455160

Issue type

Common Stock

TNGX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TNGX

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at  go-forward dose Registrational Phase 3 study of vopimetostat plus daraxonrasib as front-line treatment for patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Data from vopimetostat monotherapy in non-small cell lung cancer (NSCLC) and brain-penetrant TNG456 in NSCLC, glioblastoma and other cancers and development strategy in lung cancer expected to be disclosed in January 2027 Cash position of $977.5 million as of September 30, 2026 BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. “In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer,” said Malte Peters, MD, President and Chief Executive Officer of Tango.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer and Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) is now open for enrollment. “The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers,” said Malte Peters, M.D.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim's 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity

Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. Company's combination therapy showed an 82% ORR and 88% 9-month PFS, with median PFS not yet reached, supporting advancement to phase 3. Phase 3 registrational trial for 1st-line patients is anticipated in 1H 2027, with potential accelerated approval pathway for 2nd-line patients possible.

news source

Seeking Alpha • Oct 30, 2026

news preview

Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's strong cash position ($1B), FDA-aligned registrational design, and underappreciated dual-primary endpoint trial. Vopimetostat enables daraxonrasib dose-sparing, reducing toxicity and cost, making TNGX a preferred RAS combination partner with expanding partnership optionality.

news source

Seeking Alpha • Oct 28, 2026

news preview

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

news source

Zacks Investment Research • Oct 26, 2026

news preview

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.

news source

Investors Business Daily • Oct 23, 2026

news preview

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.

news source

MarketBeat • Oct 23, 2026

news preview

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.

news source

Benzinga • Oct 23, 2026

news preview

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

news source

Seeking Alpha • Oct 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tango Therapeutics Inc.

Open an M1 investment account to buy and sell Tango Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TNGX on M1